Bortezomib Injection, Powder, Lyophilized, For Solution
Product Images NDC 31722-303

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Bortezomib (NDC 31722-303). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Camber Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bortezomoib-inner-carton (Bortezomoib Inner Carton)

Folded carton packaging label for Bortezomib 3.5 mg injection powder, lyophilized, for solution by Camber Pharmaceuticals, Inc. The label includes reconstitution instructions for subcutaneous and intravenous injection using 0.9% sodium chloride to achieve specified final concentrations and volumes.*

FDA Label Image

Bortezomoib-outer-carton (Bortezomoib Outer Carton)

The packaging label is for Bortezomib for Injection, 3.5 mg per vial, a lyophilized powder for solution by Camber Pharmaceuticals, Inc. It is indicated for intravenous or subcutaneous use. The label includes dosage reconstitution instructions, storage information, a cautionary note that it is a cytotoxic agent, and manufacturer's details for Hetero Labs Limited in India. The label also contains barcodes and regulatory warnings.*

FDA Label Image

Bortezomoib-reconstitution-label (Bortezomoib Reconstitution Label)

An instructional illustration showing preparation instructions for Bortezomib for Injection as subcutaneous and intravenous injections. For subcutaneous use, add 1.4 mL of 0.9% sodium chloride to achieve a 2.5 mg/mL concentration; for intravenous use, add 3.5 mL of 0.9% sodium chloride to achieve 1 mg/mL. The image directs users to place corresponding stickers on vials and syringes and references the package insert for full instructions.*

FDA Label Image

Bortezomoib-vial-label (Bortezomoib Vial Label)

Label for Bortezomib for Injection, 3.5 mg per vial, lyophilized powder for solution, intended for intravenous or subcutaneous use. The single-dose vial label indicates it is a cytotoxic agent and prescription only. Manufacturer details include Camber Pharmaceuticals, Inc. and HETERO LABS LIMITED, India. Storage instructions and contact information are also shown.*

FDA Label Image

Figure1 (Figure1)

A Kaplan-Meier survival curve comparing the percentage of patients over time in months between two treatment groups labeled Vc-MP and MP. The y-axis indicates the percentage of patients from 0 to 100, and the x-axis represents time in months from 0 to 26. The chart includes the number of patients at risk at various time points and a p-value from a log-rank test for statistical comparison.*

FDA Label Image

Figure2 (Figure2)

A survival curve graph showing the percentage of patients over time (in months) comparing two treatments, labeled Vc-MP and MP. The Y-axis represents the percentage of patients, and the X-axis shows time in months up to 78. The graph includes patient numbers at risk at various time points and notes a p-value less than 0.05 from a log-rank test.*

FDA Label Image

Figure3 (Figure3)

A Kaplan-Meier survival curve comparing the proportion of patients over time (days) for treatments with Bortezomib and Dexamethasone. The graph shows patient counts at intervals and indicates a statistical p-value from a log-rank test. The y-axis represents the proportion of patients, and the x-axis represents time in days.*

FDA Label Image

Figure4 (Figure4)

A survival curve chart comparing the effects of Bortezomib and Dexamethasone over time in days, indicating patient counts at specific intervals. The graph shows the proportion of patients remaining over a period of up to 450 days, with Bortezomib maintaining a higher survival proportion than Dexamethasone throughout the timeframe.*

FDA Label Image

Figure5 (Figure5)

This Kaplan-Meier survival curve compares the percentage of patients over time (months) between two treatment groups, VcR-CAP and R-CHOP. The chart includes a log rank test p-value (<0.001) indicating statistical significance. Below the graph, the number of subjects at risk at various time points is shown for each group.*

FDA Label Image

Figure6 (Figure6)

A Kaplan-Meier survival curve showing the percentage of subjects alive over time in months from randomization. The chart compares two treatment groups labeled VcR-CAP and R-CHOP, with VcR-CAP represented by a solid line and R-CHOP by a dashed line. Below the graph, a table displays the number of subjects at risk at various time points for both groups. A hazard ratio with 95% confidence interval is also shown on the graph.*

FDA Label Image

Structure (Structure)

Chemical structure of Bortezomib, showing its molecular framework with key functional groups including a boronic acid moiety and peptide backbone.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.